Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection

European Urology

Volumn 57, Issue 6, 2010, Pages 921-927

  Jansen, Flip H ^a   van Schaik, Ron H N ^a   Kurstjens, Joep ^a   Horninger, Wolfgang ^b   Klocker, Helmut ^b   Bektic, Jasmin ^b   Wildhagen, Mark F ^a   Roobol, Monique J ^a   Bangma, Chris H ^a   Bartsch, Georg ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

BPHA; p2PSA; Prostate cancer screening; PSA isoforms

Indexed keywords

ISOPROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GLEASON SCORE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; SENSITIVITY AND SPECIFICITY;

AGED; AREA UNDER CURVE; HEALTH STATUS INDICATORS; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; ROC CURVE; STATISTICS, NONPARAMETRIC;

EID: 77951621115     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.02.003     Document Type: Article

References (23)

1. Linton H.J., Marks L.S., Millar L.S., et al. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 49 (2003) 253-259
2. Mikolajczyk S.D., Marker K.M., Millar L.S., et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61 (2001) 6958-6963
3. Mikolajczyk S.D., Millar L.S., Marker K.M., et al. Seminal plasma contains "BPSA" a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia. Prostate 45 (2000) 271-276
4. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 60 (2000) 756-759
5. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. "BPSA" a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55 (2000) 41-45
6. Peter J., Unverzagt C., Krogh T.N., Vorm O., and Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 61 (2001) 957-962
7. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170 (2003) 2181-2185
8. Mikolajczyk S.D., Catalona W.J., Evans C.L., et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50 (2004) 1017-1025
9. Naya Y., Fritsche H.A., Bhadkamkar V.A., et al. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer. Urology 63 (2004) 492-498
10. Naya Y., Fritsche H.A., Bhadkamkar V.A., et al. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urol Oncol 23 (2005) 16-21
11. Sokoll L.J., Wang Y., Feng Z., et al. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 180 (2008) 539-543 discussion 543
12. Stephan C., Kahrs A.M., Cammann H., et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 69 (2009) 198-207
13. Canto E.I., Singh H., Shariat S.F., et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 63 (2004) 905-910 discussion 910-1
14. Stephan C., Cammann H., Deger S., et al. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. Urology 74 (2009) 873-877
15. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 171 (2004) 2239-2244
16. de Vries S.H., Raaijmakers R., Blijenberg B.G., et al. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology 65 (2005) 926-930
17. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320-1328
18. Bartsch G., Horninger W., Klocker H., et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 101 (2008) 809-816
19. Berger A.P., Deibl M., Steiner H., et al. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 64 (2005) 240-245
20. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988) 837-845
21. Hugosson J., Aus G., Lilja H., Lodding P., and Pihl C.G. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 100 (2004) 1397-1405
22. Postma R., Schröder F.H.L.H., van Leenders G.J., et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam. A comparison of two rounds of screening. Eur Urol 52 (2007) 89-97
23. van der Cruijsen-Koeter I.W., Roobol M.J., Wildhagen M.F., et al. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial. ERSPC Rotterdam. Urology 68 (2006) 615-620